Merck’s WELIREG™ (belzutifan) Receives FDA Approval
Merck has informed OSCO that WELIREG™ (belzutifan) 40-mg tablets has received FDA approval. WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. SELECTED SAFETY INFORMATION WARNING: EMBRYO-FETAL […]